BERLIN — The combination of pembrolizumab with weekly paclitaxel, with or without bevacizumab, leads to significant improvements in survival outcomes in patients with platinum-resistant recurrent ...
Zynyz addition to carboplatin and paclitaxel improved median PFS to 9.3 months versus 7.4 months with placebo in advanced SCAC patients. The trial showed enhanced overall response rate and duration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results